UnitedHealthcare completes acquisition of Health Net's Northeast licenses
UnitedHealthcare has completed the acquisition of the Northeast's licensed subsidiaries of Health Net and has obtained rights to renew Health Net's membership in Connecticut, New York and New Jersey.
UnitedHealthcare has completed the acquisition of the Northeast's licensed subsidiaries of Health Net and has obtained rights to renew Health Net's membership in Connecticut, New York and New Jersey. The transaction has received all regulatory approvals required for completion.
As Health Net's commercial customers in the Northeast reach renewal dates, UnitedHealthcare will work to enroll them in a comparable Oxford or UnitedHealthcare plan. Until members are enrolled in a replacement plan, their current Health Net benefits remain in effect under their existing Health Net contracts. There will be no interruption to coverage or payments during this transition period.
Health Net will continue to administer all of the Health Net plans - commercial, Medicare and Medicaid - in the Northeast under administrative services agreements with UnitedHealthcare until members transition to UnitedHealthcare plans.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
